caa a22 4500 445888342 CHVBK 20180317145607.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1007/s00535-011-0387-9 doi (NATIONALLICENCE)springer-10.1007/s00535-011-0387-9 Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies [Elektronische Daten] [Shinji Tanaka, Shigeki Arii] Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and its incidence is still increasing. While the primary curative treatment for HCC is surgical resection, a major obstacle for the treatment of HCC is the high frequency of tumor recurrence even after curative resection. Effective palliative treatment is hindered by the evidence that HCC is frequently resistant to conventional chemotherapy and radiotherapy. Targeted therapy which specifically inhibits molecular abnormalities has emerged as a novel approach for the innovative and effective medical treatment of malignancies. In order to fulfill this promise there is an urgent need to identify the optimal targets for the treatment of HCC. A multi-kinase angiogenesis inhibitor, sorafenib, has been revealed as the first agent to show favorable overall survival in patients with advanced HCC. A new era of HCC treatment has arrived, but there has been limited improvement in survival benefits with the status quo. This review summarizes molecular targeted therapy for HCC, with a focus on angiogenesis, growth signaling, and mitosis, as well as a promising concept, "cancer stemness” for the current and potential next strategies of HCC treatment. Springer, 2011 Hepatocellular carcinoma nationallicence Angiogenesis nationallicence Hypoxia nationallicence Cancer stem cell nationallicence Niche nationallicence Tanaka Shinji Department of Hepato-Biliary-Pancreatic Surgery, Tokyo Medical and Dental University, Graduate School of Medicine, Yushima 1-5-45, 113-8519, Tokyo, Bunkyo-ku, Japan aut Arii Shigeki Department of Hepato-Biliary-Pancreatic Surgery, Tokyo Medical and Dental University, Graduate School of Medicine, Yushima 1-5-45, 113-8519, Tokyo, Bunkyo-ku, Japan aut Journal of Gastroenterology Springer Japan 46/3(2011-03-01), 289-296 0944-1174 46:3<289 2011 46 535 https://doi.org/10.1007/s00535-011-0387-9 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00535-011-0387-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tanaka Shinji Department of Hepato-Biliary-Pancreatic Surgery, Tokyo Medical and Dental University, Graduate School of Medicine, Yushima 1-5-45, 113-8519, Tokyo, Bunkyo-ku, Japan aut NATIONALLICENCE 700 1- Arii Shigeki Department of Hepato-Biliary-Pancreatic Surgery, Tokyo Medical and Dental University, Graduate School of Medicine, Yushima 1-5-45, 113-8519, Tokyo, Bunkyo-ku, Japan aut NATIONALLICENCE 773 0- Journal of Gastroenterology Springer Japan 46/3(2011-03-01), 289-296 0944-1174 46:3<289 2011 46 535 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer